HoldingsChannel.com
Aclaris Therapeutics insider buying image
The table below summarizes the most recent Aclaris Therapeutics insider buying information, with links below the price to see the CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more information about why Aclaris Therapeutics insider buys are important for investors to follow.
DateInsiderPriceAmount
9-6-2023
Insider Buy
Kevin Balthaser
Chief Financial Officer
$7.90
CAGR »
$74,971.00
9,490 shares
8-28-2023
Insider Buy
James Loerop
Chief Business Officer
$6.80
CAGR »
$99,958.71
14,705 shares
3-17-2023
Insider Buy
Douglas J. Manion
Pres and CEO
$7.86
CAGR »
$49,532.49
6,300 shares
3-9-2023
Insider Buy
Douglas J. Manion
Pres and CEO
$7.74
CAGR »
$50,277.50
6,500 shares
10-22-2018
Insider Buy
Anand Mehra
Director
$10.75
CAGR »
$3,999,999.75
372,093 shares
5-16-2018
Insider Buy
Andrew Kenneth William Powell
Director
$19.12
CAGR »
$9,560.00
500 shares
5-7-2018
Insider Buy
Frank Ruffo
Chief Financial Officer
$18.22
CAGR »
$22,775.00
1,250 shares
4-6-2018
Insider Buy
Stephen A. Tullman
Director
$16.54
CAGR »
$441,618.00
26,700 shares
4-6-2018
Insider Buy
Frank Ruffo
Chief Financial Officer
$16.59
CAGR »
$20,737.50
1,250 shares
4-5-2018
Insider Buy
Neal Walker
President and CEO
$16.75
CAGR »
$167,500.00
10,000 shares
8-16-2017
Insider Buy
Andrew N. Schiff
Director
$23.02
CAGR »
$2,499,995.02
108,601 shares
2-23-2016
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$17.15
CAGR »
$681,469.87
39,726 shares
1-20-2016
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$19.87
CAGR »
$155,072.47
7,803 shares
1-13-2016
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$19.10
CAGR »
$298,737.76
15,637 shares
10-29-2015
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$14.00
CAGR »
$3,418,800.00
244,200 shares
10-22-2015
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$14.03
CAGR »
$75,882.82
5,410 shares
10-21-2015
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$14.89
CAGR »
$521,095.36
34,999 shares
10-14-2015
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$14.06
CAGR »
$601,792.37
42,813 shares
10-13-2015
Insider Buy
FMR LLC
>10% Owner
$11.00
CAGR »
$3,690,005.00
335,455 shares
10-13-2015
Insider Buy
Sofinnova Venture Partners VIII, L.P.
>10% Owner
$11.00
CAGR »
$4,499,990.00
409,090 shares
10-13-2015
Insider Buy
Anand Mehra
Director and >10% Owner
$11.00
CAGR »
$4,499,990.00
409,090 shares
10-13-2015
Insider Buy
VIVO VENTURES VII, LLC
>10% Owner
$11.00
CAGR »
$4,999,995.00
454,545 shares
10-13-2015
Insider Buy
Albert Cha
Director
$11.00
CAGR »
$4,999,995.00
454,545 shares
10-8-2015
Insider Buy
RA CAPITAL MANAGEMENT, LLC
>10% Owner
$10.86
CAGR »
$24,289,919.53
2,237,130 shares
10-7-2015
Insider Buy
Albert Cha
Director
$11.00
CAGR »
$146,872.00
13,352 shares
10-7-2015
Insider Buy
VIVO VENTURES VII, LLC
>10% Owner
$11.00
CAGR »
$146,872.00
13,352 shares

Also See: Institutional Holders of ACRS
Also See: SEC filings

ACRS Performance Since Insider Purchase
Below we present the annualized performance delivered by Aclaris Therapeutics stock since 9-6-2023 (the date of the most recent insider purchase). The performance of the investment from the time Aclaris Therapeutics insider buying occurred is the ultimate test of whether insiders were right about ACRS being a good buy.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 09/07/2023
End date: 04/26/2024
Start price/share: $7.57
End price/share: $1.20
Dividends collected/share: $0.00
Total return: -84.15%
Annualized Gain: -132.39%
Starting investment: $10,000.00
Ending investment: $1,585.00
Years: 0.64

Aclaris Therapeutics Insider Buying

This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Aclaris Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).

Also See: Funds Holding ACRS

Quotes delayed 20 minutes

Email EnvelopeFree ACRS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Other companies seeing insider buying close in time to when the Aclaris Therapeutics Insider Buying occurred are:

Vicor Insider Buying
Hormel Foods Insider Buying
Sabra Health Care REIT Insider Buying
Douglas Dynamics Insider Buying
Lamar Advertising Co (New) Insider Buying
Catalent Insider Buying
DigitalOcean Holdings Insider Buying
Foot Locker Insider Buying
1-800 Flowers.com Insider Buying
NRX Pharmaceuticals Insider Buying

Aclaris Therapeutics Insider Buying | www.HoldingsChannel.com

Copyright © 2013 - 2024, All Rights Reserved Nothing in Holdings Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Holdings Channel; Meet Our Editorial Staff.